Teknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Rhea-AI Summary
Teknova (Nasdaq: TKNO) will report fourth-quarter and full-year 2025 financial results on February 26, 2026 after market close.
The company will host a live webcast and conference call on February 26, 2026 at 5:30 p.m. Eastern Time, with a replay available on the investor website about two hours after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, TKNO declined NaN%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TKNO fell 5.74% while several peers were also negative (e.g., ACB -8.21%, IRWD -6.56%, SXTC -1.5%, LFCR -1.86%), but no names appeared in the momentum scanner and OGI was flat, pointing to more stock-specific than coordinated sector flow.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 earnings | Positive | -2.8% | Reported Q3 revenue growth, margin improvement, and narrower net loss. |
| Oct 28 | Earnings date notice | Neutral | +0.0% | Announced Q3 2025 earnings release date and post-close conference call. |
| Aug 07 | Q2 2025 earnings | Positive | -2.5% | Delivered Q2 revenue growth and higher gross margin with smaller net loss. |
Recent earnings reports showed revenue growth and margin improvement, yet TKNO saw modest share price declines after both Q2 and Q3 2025 results, suggesting a pattern of cautious or skeptical reactions to fundamentally positive updates.
Over the past few quarters, Teknova has reported steady growth and margin improvement. Q2 2025 revenue was $10.3M and Q3 2025 reached $10.5M, extending a streak of year-over-year growth, while losses narrowed and cash remained solid. Despite these trends, the stock moved -2.53% after Q2 results and -2.83% after Q3 results. The current earnings-date announcement on Feb 26, 2026 fits into this cadence of regular quarterly updates.
Regulatory & Risk Context
The company has an active Form S-3 shelf registration dated Jul 10, 2025, currently noted as not yet effective with no recorded usage. This filing provides a framework for potential future securities offerings once effective, but no specific takedowns have been disclosed in the provided data.
Market Pulse Summary
This announcement sets the schedule for Teknova’s Q4 and full year 2025 results on February 26, 2026, continuing its regular cadence of quarterly communication. Recent history showed revenue growth and margin improvement, yet shares sat near a 52-week low of $2.155 and below the $4.93 200-day MA before this update. Investors may watch how upcoming results relate to existing credit covenants, cash trends, and any future use of the currently unused S-3 filing framework.
Key Terms
molecular diagnostics medical
webcast technical
AI-generated analysis. Not financial advice.
HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, following the close of market.
Teknova will host a webcast and conference call on Thursday, February 26, 2026, beginning at 5:30 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to participate in the call, please register for the webcast here to receive a unique PIN number and dial-in information. The webcast will be available for replay on the Company’s website approximately two hours after the event.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel breakthroughs that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in molecular diagnostics, synthetic biology, and emerging therapeutic modalities. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 180,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of next-generation therapies.
Investor Contact
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
This press release was published by a CLEAR® Verified individual.